# A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

> **NCT03626636** · PHASE2 · COMPLETED · sponsor: **Allegro Ophthalmics, LLC** · enrollment: 42 (actual)

## Conditions studied

- Dry Age-related Macular Degeneration

## Interventions

- **DRUG:** Risuteganib
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT03626636
- **Lead sponsor:** Allegro Ophthalmics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2019-04-04
- **Final completion:** 2019-04-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626636, "A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03626636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*